Source comparison
Selank Amidate vs Semax Amidate: Research Comparison
This table distills the core distinctions between Selank Amidate and Semax Amidate across mechanism, application, and protocol design considerations. Each difference matters when selecting the correct peptide for a specific research model. Primary Mechanism GA
This comparison does not assign a generated winner or score.
- This table distills the core distinctions between Selank Amidate and Semax Amidate across mechanism, application, and protocol design considerations. Each difference matters when selecting the correct peptide for a specific research model.
- Primary Mechanism
- GABAergic modulation, IL-6 suppression, enkephalin receptor binding
- BDNF/NGF upregulation via MC4R/MC5R activation, PI3K/Akt pathway enhancement
- Mechanistically non-overlapping. No functional redundancy between compounds
- Half-Life (Amidate Form)
- 90–120 minutes post-administration
- Amidate modification provides identical stability extension for both peptides
- Cognitive Effect Onset
- 45–90 minutes (indirect via cortisol reduction)
- 3–6 hours (direct via neurotrophin synthesis)
- Selank acts faster but through anxiety reduction; Semax requires protein synthesis time
- Optimal Dosing (Rodent Models)
- 50–300 mcg/kg intranasal or subcutaneous
- 300–600 mcg/kg intranasal or subcutaneous
- Semax requires 2–4× higher dosing for measurable cognitive outcomes
- Research Applications
- Anxiety models, stress-induced memory impairment, neuroinflammation, immune modulation
- Cognitive enhancement, stroke recovery, neurodegenerative disease, neuroprotection
- Select based on primary outcome. Anxiolytic vs neuroplasticity
- Receptor Targets
- Leucine-enkephalin receptors, GABA-A (indirect modulation)
- Melanocortin receptors (MC4R, MC5R), TrkB (via BDNF elevation)
- Receptor profiles have zero overlap. Substitution is not viable